



07046098

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 19b-4(e)

SECURITIES AND EXCHANGE COMMISSION

JAN 26 2007
DIVISION OF REGULATION

Information Required of a Self-Regulatory Organization Listing and Trading a New Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM 19b-4(e)

Part I Initial Listing Report

- Name of Self-Regulatory Organization Listing New Derivative Securities Product:
New York Stock Exchange LLC
- Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
Open-end Management Investment Company
- Class of New Derivative Securities Product:
Investment Company Units (Exchange-Traded Funds)
- Name of Underlying Instrument:
HealthShares™ Emerging Cancer Index; HealthShares™ Cardiology Devices Index; HealthShares™ Diagnostics Index; HealthShares™ Patient Care Services Index; HealthShares™ Enabling Technologies Index
- If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:
Narrow-Based
- Ticker Symbol(s) of New Derivative Securities Product:
HealthShares™ Emerging Cancer Exchange-Traded Fund (Symbol: HHJ); HealthShares™ Cardiology Devices Exchange-Traded Fund (HHE); HealthShares™ Diagnostics Exchange-Traded Fund (HHD); HealthShares™ Patient Care Services Exchange-Traded Fund (HHB); HealthShares™ Enabling Technologies Exchange-Traded Fund (HHV)
- Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:
NYSE and Nasdaq (for HHE, HHB, HHV); Nasdaq, Amex (for HHJ); NYSE, Nasdaq and Amex (for HHD)
- Settlement Methodology of New Derivative Securities Product:
Regular way trade settle on T+3/ Book-entry only held in DTC
- Position Limits of New Derivative Securities Product (if applicable):
Not Applicable

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

Mary Yeager

Title: Assistant Secretary

Telephone Number: 212-656-2062

Manual Signature of Official Responsible for Form:

Date: January 26, 2007

Mary Yeager

PROCESSED
3 MAR 12 2007
COMMISSION
FINANCIAL

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	JANUARY 29, 2007 <i>in</i>

Mary Yeager
Assistant Secretary

New York Stock Exchange LLC
11 Wall Street
New York, NY 10005



tel: 212.656.2062
fax: 212.656.3939
myeager@nyse.com

January 26, 2007

SECURITIES AND EXCHANGE COMMISSION
RECEIVED
JAN 29 2007

Gail Jackson
Paralegal Specialist
Division of Market Regulation
Securities and Exchange Commission
100 F Street, NE
Room 6628
Washington, DC 20549

DIVISION OF MARKET REGULATION

Re: Form 19b-4(e) for 5 HealthShares Exchange-Traded Funds

Dear Ms. Jackson:

Pursuant to Rule 19b-4(e) under the Securities Exchange Act of 1934, New York Stock Exchange LLC ("Exchange") encloses for filing one original and nine copies of a Form 19b-4(e) for

- HealthShares™ Emerging Cancer Exchange-Traded Fund (HHJ)
- HealthShares™ Cardiology Devices Exchange-Traded Fund (HHE)
- HealthShares™ Diagnostics Exchange-Traded Fund (HHD)
- HealthShares™ Patient Care Services Exchange-Traded Fund (HHB)
- HealthShares™ Enabling Technologies Exchange-Traded Fund (HHV).

These Funds began trading on the Exchange on a fully listed basis on January 23, 2007. The New York Stock Exchange's rules for listing and trading products of this nature are found in Section 703.16 of the Exchange's Listed Company Manual.

Sincerely,

Mary Yeager

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	JANUARY 29, 2007

END